Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer
| Autor: | Jinpo Yang, Jindai Zhang, Wei Zhang, Bin Zhang, Yonglei Zhang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.medical_treatment FLOT chemotherapy Gastroenterology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Mucositis Apatinib Neoadjuvant therapy Original Research Chemotherapy FLOTA business.industry toxicity medicine.disease Oxaliplatin LAGC Regimen 030104 developmental biology Oncology chemistry Docetaxel Fluorouracil Cancer Management and Research 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Cancer Management and Research |
| ISSN: | 1179-1322 1978-2020 |
| Popis: | Yonglei Zhang,1 Bin Zhang,1 Jinpo Yang,2 Jindai Zhang,1 Wei Zhang3 1Department of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan Province, People’s Republic of China; 2Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan Province, People’s Republic of China; 3Department of Gastrointestinal Surgery, Henan Provincial People’s Hospital, Zhengzhou, 450008, Henan Province, People’s Republic of ChinaCorrespondence: Bin Zhang Email zhangbin19782020@163.comPurpose: The trend in neoadjuvant therapy for locally advanced gastric cancer (LAGC) is to use more drugs or therapies in combination. This study aimed to assess the safety and effectiveness of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus apatinib in the treatment of LAGC.Patients and Methods: We collected clinical data from patients with LAGC who received neoadjuvant FLOT and apatinib therapy and underwent surgery from January 2017 to December 2020. Patients were divided into either the FLOT group (in which patients received FLOT neoadjuvant therapy and surgery) or the FLOTA group (in which patients received FLOT plus apatinib neoadjuvant therapy and surgery).Results: The FLOT and FLOTA groups contained 44 and 31 patients, respectively. There were significant differences between the FLOT and FLOTA groups in the objective response rate (50.00% vs. 80.65%, respectively, p = 0.008) and average change from baseline in the target lesion size (− 26.16 ± 34.61 vs. − 54.32 ± 36.11, respectively, p < 0.001). There were also significant differences in the pretreatment clinical tumor-node-metastasis (cTNM) and post treatment cTNM stages for the FLOT group (p = 0.001) and for the FLOTA group (p < 0.001). There were no significant differences between the FLOT and FLOTA groups in post neoadjuvant therapy cTNM stages (p = 0.525), R0 rate (p = 0.397), tumor regression grade (p = 0.397), or post treatment pathological TNM stage (p = 0.180). Some neoadjuvant therapy-related adverse events occurred significantly more frequently in the FLOTA group, including diarrhea (all grades), pain (all grades), oral mucositis (all grades), and hand-foot syndrome (all grades).Conclusion: The FLOTA regimen can achieve better perioperative efficacy and acceptable toxicity compared with that of the FLOT regimen in neoadjuvant treatment of LAGC. The FLOTA regimen for neoadjuvant therapy for LAGC merits further study.Keywords: chemotherapy, FLOT, FLOTA, LAGC, toxicity |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|